Durata Therapeutics
Encyclopedia
Durata Therapeutics, established in 2009, is a clinical development stage pharmaceutical company. Durata focuses on new therapeutics to treat infectious diseases.
Durata has several projects in its pipeline, most notably the antibacterial, dalbavancin
. The company acquired this long-acting semisynthetic lipoglycopeptide
antibiotic from Pfizer
in December 2009. Durata has since initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.
Durata has several projects in its pipeline, most notably the antibacterial, dalbavancin
Dalbavancin
Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus .Dalbavancin is a novel semisynthetic...
. The company acquired this long-acting semisynthetic lipoglycopeptide
Lipoglycopeptide
Lipoglycopeptides are a class of antibiotic that have lipophilic side-chains linked to glycopeptides. The class includes oritavancin, telavancin and dalbavancin.Telavancin is the most potent of the 3 against Clostridium spp....
antibiotic from Pfizer
Pfizer
Pfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
in December 2009. Durata has since initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections.